[Attempt to treat a case of chronic familial granulomatous disease by allogenic bone marrow transplantation].

A bone marrow graft was performed in a 3 1/2 year old boy suffering from chronic granulomatous disease. Donor-recipient matching was complete in the ABO, HL-A and M.L.C. systems. The number of injected cells amounted to 5.4 X 10(9) (3.6 X 10(8) cells/kg body weight). The immunosuppression regimen consisted of cyclophosphamide and A.L.S. before the graft, and methotrexate after it. Neither graft versus host reaction, nor secondary infection developed. The take of the graft was monitored by the Gm allotypes. Rejection, however, occurred after 2 months.

The antiglobulin microcytotoxicity assay in HL-A genotyped families.

HL-A genotyping was accomplished in 30 families (8 black, 21 white, and 1 American Indian) based on serological results obtained by our ususal lymphocytotoxicity assays. Each family was further tested by an antiglobulin microcytotoxicity method. Segregation patterns obtained by the latter method, compared with those of the former, showed few discrepancies. HL-A-identical siblings were serologically similar by the antiglobulin assay with frequency of discordant reactions at the same level as that of our regular two-stage lymphocytotoxicity assay. The antiglobulin method was shown to be highly reproducible with 1.3% discordance between duplicate tests. Many sera employed in routine cytotoxicity testing gave positive reactions with all family members in the antiglobulin assay (39% all positive by antiglobulin versus 16% by the regular cytotoxicity test), so that this method has limited usefulness for routine HL-A typing. The antiglobulin assay may have particular value, however, for identifying HL-A haplotypes in families, especially non-Caucasian, which give infrequent positive reactions in the usual lymphocytotoxicity assays.